Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 237

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 237
---
Our
business, financial condition and operating results are subject to a number of risk factors, both those that are known to us and
identified below and others that may arise from time to time. These risk factors could cause our actual results to differ materially
from those suggested by forward-looking statements in this Report and elsewhere, and may adversely affect our business, financial
condition or operating results. If any of these risk factors should occur, moreover, the trading price of our securities could
decline, and investors in our securities could lose all or part of their investment in our securities. These risk factors should
be carefully considered in evaluating our prospects.

27 

Summary
of Risk Factors

Our
business is subject to a number of risks that you should be aware of before making an investment decision to purchase our securities.
You should carefully consider all of the information set forth in this Report and, in particular, should evaluate the specific
factors set forth in the section titled “Risk Factors” in deciding whether to invest in our securities. Among these
important risks are the following:

    ●
    The report of the
    independent registered public accounting firm on our 2024 and 2023 financial statements contains a going concern qualification;

    ●
    We are a clinical
    stage biopharmaceutical company with a limited operating history;

    ●
    We have incurred
    net losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability;

    ●
    We have identified
    material weaknesses in our internal control over financial reporting;

    ●
    We will need to
    raise additional funding to receive approval for CC8464, CT2000, CT3000 or any other future compound. Such funding may not
    be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit,
    sell or terminate certain of our product development efforts or other operations;

    ●
    We may be subject
    to litigation for a variety of claims, which could adversely affect our results of operations, harm our reputation or otherwise
    negatively impact our business;

    ●
    We are early in
    our efforts to develop CC8464, which is the only compound that we have advanced into clinical development. If we are unable
    to advance CC8464 through clinical trials, obtain regulatory approval and ultimately commercialize CC8464, or if we experience
    significant delays in doing so, our business